Status:
RECRUITING
Prospective Observational Clinical Follow-up of Euromi Biosciences Pre-filled Silicone Gel Breast Implants
Lead Sponsor:
Euromi Biosciences
Conditions:
Breast Implant Rupture
Breast Implant; Complications
Eligibility:
FEMALE
18-60 years
Brief Summary
Prospective observational clinical follow-up of Euromi Biosciences silicone gel-filled breast implants - Post-market clinical investigation - ELEGANT
Eligibility Criteria
Inclusion
- Female;
- 18 years old and above, and under 60 years old;
- has approved and signed the informed consent form;
- eligible to receive at least one EUROMI Biosciences implant during breast reconstruction following a mastectomy or during aesthetic breast surgery;
- Willing to be followed up for a period of 10 years.
Exclusion
- Informed pregnancy or breastfeeding at the time of inclusion
- Known hypersensitivity and / or allergy to silicone;
- Not understanding or not accepting the risks of further surgeries during follow-up;
- Body mass index \> 40 kg/m²;
- Diabetes
- HbA1c levels \> 7,5%;
- History of repeated failure with the implantation of similar implants;
- Tissue or fat insufficiency;
- Progressive breast cancer large tumours (\>5 cm), late cancer stage and deep tumours;
- Grossly positive axillary involvement / or chest wall involvement;
- High risk of cancer recurrence;
- Tissue damage in the implant area due to irradiation of the thoracic wall;
- Pre-existing pathology in the implant area;
- General infection or infection in the implant area;
- Medical condition (poor physiological condition, psychological instability, severe smoking, obesity, coagulopathy, diabetes, severe cardiovascular or pulmonary disease, etc.) Which may, according to the judgement of the surgeon, entail excessive risk and/or post-surgical complications;
- History or presence of an autoimmune disease;
- Immunocompromised;
- History or current treatment using radiation with lower-pole scarring and thin, poorly vascularized skin/tissue / microwave diathermy / or steroids;
- Medical condition likely to interfere with her capacity to understand the follow-up requirements, to participate in the follow-up or to give her informed consent;
- Concomitantly part of another interventional clinical trial.
- Under supervision or legal guardianship
- Deprived of liberty by a judicial or administrative decision
- Not affiliated to health insurance system or is a beneficiary of such coverage
Key Trial Info
Start Date :
October 18 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
September 1 2034
Estimated Enrollment :
177 Patients enrolled
Trial Details
Trial ID
NCT05987475
Start Date
October 18 2023
End Date
September 1 2034
Last Update
November 29 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CHRU Nancy
Nancy, France